Skip to main content
SpringerLink
Log in

The Effectiveness of the Treatment of Octreotide on Chylous Ascites After Liver Cirrhosis

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Octreotide is a crucial drug used for treating patients with chylous ascites; however, there have been few reports related to octreotide that are being used in cirrhotic patients. Thus, this thesis is designed to determine the effects of octreotide on patients with chylous ascites after liver cirrhosis. Eight patients were diagnosed with chylous ascites, on the basis of laboratory findings on ascites samples, between January 2003 and May 2008. Octreotide was given to the six patients, while the remaining two were treated as a control. All patients had persistent peritonea drainage with the quantity and quality of the drainage fluid observed once every other day. All the necessary care was individually given to the patients during the therapy. All patients properly received combined therapy including a low-fat and low-sodium diet, and diuretic and peritoneal drainage. The volume of the peritoneal drainage was reduced to zero in one of the six patients who received octreotide therapy, while the other five had the drainage volumes decreased from 2,000 to 50 ml with a clear appearance and negative qualitative analysis of chyle. For those two patients who did not receive octreotide therapy, the conditions of peritoneal drainage seldom changed both from the qualitative and quantitative aspects. In conclusion, Octreotide, along with combined therapy, can rapidly relieve portal hypertension and reduce triglyceride levels in ascites. It appears to be an effective therapy available for the treatment of chylous ascites caused by liver cirrhosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Losanoff JE, Richman BW, Jones JW. Chylous ascites. Am J Gastroenterol. 2003;98(1):219–220. doi:10.1111/j.1572-0241.2003.07203.x.

    Article  PubMed  Google Scholar 

  2. Mincher L, Evans J, Jenner MW, et al. The successful treatment of chylous effusions in malignant disease with octreotide. Clin Oncol (R Coll Radiol). 2005;17(2):118–121. doi:10.1016/j.clon.2004.06.016.

    CAS  Google Scholar 

  3. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology. 2001;120(3):726–748. doi:10.1053/gast.2001.22580.

    Article  PubMed  CAS  Google Scholar 

  4. Gómez Soto FM, Marcos Sánchez F, Franco Moreno AI, et al. Chylous ascites chylosus as a manifestation of hepatocarcinoma. Gastroenterol Hepatol. 2003;26(4):276–277. doi:10.1157/13045206.

    Article  PubMed  Google Scholar 

  5. Castellote J, Porta F. Chylous ascites secondary to liver cirrhosis. Rev Esp Enferm Dig. 1994;86(6):912–914.

    PubMed  CAS  Google Scholar 

  6. Bhatia C, Pratap U, Slavik Z. Octreotide therapy: a new horizon in treatment of iatrogenic chyloperitoneum. Arch Dis Child. 2001;85(3):234–235. doi:10.1136/adc.85.3.234.

    Article  PubMed  CAS  Google Scholar 

  7. Cheung CK, Khwaja A. Chylous ascites: an unusual complication of peritoneal dialysis. A case report and literature review. Perit Dial Int. 2008;28(3):229–231.

    PubMed  Google Scholar 

  8. Proveoza JM, Banoon BR. Chyloperitoneum associated with sarcoidoses. Am J Gastroenterol. 1993;88(9):1462–1463.

    Google Scholar 

  9. Rovira E, Moles JR, Hinojosa J, Primo J, Gonzalvo F, Albert A. Dysfunction of a TIPS-transjugular intrahepatic porto-systemic shunt and chylous ascites. Rev Esp Enferm Dig. 1997;89:475.

    PubMed  CAS  Google Scholar 

  10. Ehrenpreis ED, Boiskin I, Schaefer K. Chylous ascites in a patient with mesenteric panniculits. J Clin Gastroenterol. 2008;42(3):327–328.

    PubMed  Google Scholar 

  11. Romero S, Martín C, Hernandez L, et al. Chylothorax in cirrhosis of the liver: analysis of its frequency and clinical characteristics. Chest. 1998;114(1):154–159. doi:10.1378/chest.114.1.154.

    Article  PubMed  CAS  Google Scholar 

  12. Mishra R, Kumar S. Octreotide in congenital chylous ascites an avoid requirement of total parenteral nutrition. Indian J Gastroenterol. 2007;26(6):299–300.

    PubMed  Google Scholar 

  13. Nakamura T, Kudoh K, Takebe K, et al. Octreotide decreases biliary and pancreatic exocrine function and induces steatorrhea in healthy subjects. Intern Med. 1994;33(10):593–596. doi:10.2169/internalmedicine.33.593.

    Article  PubMed  CAS  Google Scholar 

  14. Collard JM, Laterre PF, Boemer F, Reynaert M, Ponlot R. Conservative treatment of postsurgical lymphatic leaks with somatostatin-14. Chest. 2000;117(3):902–905. doi:10.1378/chest.117.3.902.

    Article  PubMed  CAS  Google Scholar 

  15. Reubi JC, Horisberger U, Waser B, Gebbers JO, Laissue J. Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology. 1992;103(4):1207–1214.

    PubMed  CAS  Google Scholar 

  16. Ferrandière M, Hazouard E, Guicheteau V, Gouchet A, et al. Chylous ascites following radical nephrectomy: efficiency of octreotide as treatment of a ruptured thoracic duct. Intensive Care Med. 2000;26(4):484–485. doi:10.1007/s001340051190.

    Article  PubMed  Google Scholar 

  17. Lee PH, Lin CL, Lai PC, Yang CW. Octreotide therapy for chylous ascites in a chronic dialysis patient. Nephrology (Carlton). 2005;10(4):344–347. doi:10.1111/j.1440-1797.2005.00427.x.

    Article  Google Scholar 

  18. Leong RW, House AK, Jeffrey GP. Chylous ascites caused by portal vein thrombosis treated with octreotide. J Gastroenterol Hepatol. 2003;18(10):1211–1213. doi:10.1046/j.1440-1746.2003.02850.x.

    Article  PubMed  Google Scholar 

  19. Huang Q, Jiang ZW, Jiang J, et al. Chylous ascites: treated with total parenteral nutrition and somatostatin. World J Gastroenterol. 2004;10(17):2588.

    PubMed  CAS  Google Scholar 

  20. Shapiro AM, Brain VG, Sigalet DL. Rapid resolution of chylous ascites after liver transplantation using somatostatin analog and total nutrition. Transplantation. 1996;61:1410–1411. doi:10.1097/00007890-199605150-00023.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Comprehensive Treatment II, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 225 Changhai Road, Shanghai, China

    Dong Xun Zhou, Hua Bang Zhou, Qing Wang, Shan Shan Zou, Hao Wang & He Ping Hu

Authors
  1. Dong Xun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hua Bang Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shan Shan Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. He Ping Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to He Ping Hu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhou, D.X., Zhou, H.B., Wang, Q. et al. The Effectiveness of the Treatment of Octreotide on Chylous Ascites After Liver Cirrhosis. Dig Dis Sci 54, 1783–1788 (2009). https://doi.org/10.1007/s10620-008-0566-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-008-0566-6

Keywords

Search

Navigation